Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Overview of the Company - Editas is an in vivo CRISPR therapeutics company focused on delivering CRISPR editing machinery through intravenous infusion using lipid nanoparticles [1] Differentiation in Gene Editing - The company differentiates itself by using CRISPR for applications that other modalities cannot achieve, specifically targeting noncoding DNA to enhance the expression of disease-mitigating proteins [2] - An example of this approach is the LDL receptor upregulation program, EDIT-401, which has demonstrated the ability to reduce LDL cholesterol levels by 90% across multiple animal species, including nonhuman primates, indicating its potential to transform cardiovascular disease management [2]